Unknown

Dataset Information

0

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes.


ABSTRACT: The investigation of interleukin 1beta (IL-1beta) in human inflammatory diseases is hampered by the fact that it is virtually undetectable in human plasma. We demonstrate that by administering the anti-human IL-1beta antibody canakinumab (ACZ885) to humans, the resulting formation of IL-1beta-antibody complexes allowed the detection of in vivo-produced IL-1beta. A two-compartment mathematical model was generated that predicted a constitutive production rate of 6 ng/d IL-1beta in healthy subjects. In contrast, patients with cryopyrin-associated periodic syndromes (CAPS), a rare monogenetic disease driven by uncontrolled caspase-1 activity and IL-1 production, produced a mean of 31 ng/d. Treatment with canakinumab not only induced long-lasting complete clinical response but also reduced the production rate of IL-1beta to normal levels within 8 wk of treatment, suggesting that IL-1beta production in these patients was mainly IL-1beta driven. The model further indicated that IL-1beta is the only cytokine driving disease severity and duration of response to canakinumab. A correction for natural IL-1 antagonists was not required to fit the data. Together, the study allowed new insights into the production and regulation of IL-1beta in man. It also indicated that CAPS is entirely mediated by IL-1beta and that canakinumab treatment restores physiological IL-1beta production.

SUBMITTER: Lachmann HJ 

PROVIDER: S-EPMC2715040 | biostudies-literature | 2009 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes.

Lachmann Helen J HJ   Lowe Philip P   Felix Sandra Daniela SD   Rordorf Christiane C   Leslie Kieron K   Madhoo Sheril S   Wittkowski Helmut H   Bek Stephan S   Hartmann Nicole N   Bosset Sophie S   Hawkins Philip N PN   Jung Thomas T  

The Journal of experimental medicine 20090413 5


The investigation of interleukin 1beta (IL-1beta) in human inflammatory diseases is hampered by the fact that it is virtually undetectable in human plasma. We demonstrate that by administering the anti-human IL-1beta antibody canakinumab (ACZ885) to humans, the resulting formation of IL-1beta-antibody complexes allowed the detection of in vivo-produced IL-1beta. A two-compartment mathematical model was generated that predicted a constitutive production rate of 6 ng/d IL-1beta in healthy subjects  ...[more]

Similar Datasets

| S-EPMC2906851 | biostudies-other
| S-EPMC5074783 | biostudies-literature
| S-EPMC4323990 | biostudies-literature
| S-EPMC4957676 | biostudies-literature
| S-EPMC4464681 | biostudies-literature
| S-EPMC6743338 | biostudies-literature
| S-EPMC4487522 | biostudies-literature
| S-EPMC5671490 | biostudies-literature
| S-EPMC7711157 | biostudies-literature
| S-EPMC7794776 | biostudies-literature